Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities Growth (1y) (2011 - 2026)
Powered by 
Analysis
Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | Jazz Pharmaceuticals | 15.60 Bn | 13.98 Bn | 1.09 Bn | 155.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 155.37% |
| Mar 31, 2026 | 172.84% |
| Dec 31, 2025 | -92.54% |
| Sep 30, 2025 | -253.09% |
| Jun 30, 2025 | -149.33% |
| Mar 31, 2025 | 37.85% |
| Dec 31, 2024 | -289.87% |
| Sep 30, 2024 | 222.83% |
| Jun 30, 2024 | -199.85% |
| Mar 31, 2024 | -5,538.82% |
| Dec 31, 2023 | 131.38% |
| Sep 30, 2023 | -3,887.46% |
| Jun 30, 2023 | 3.84% |
| Mar 31, 2023 | 87.07% |
| Dec 31, 2022 | -3,114.21% |
| Sep 30, 2022 | 117.16% |
| Jun 30, 2022 | 98.49% |
| Mar 31, 2022 | -105.06% |
| Dec 31, 2021 | -113.78% |
| Sep 30, 2021 | 90.41% |